Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

How to Use TB-500: A Researcher’s Protocol for Purity & Precision

In the world of peptide research, few compounds generate as much consistent buzz as TB-500. It’s a molecule that holds immense promise across various fields of study, from tissue regeneration to inflammatory response modulation. But with great potential comes

In the world of peptide research, few compounds generate as much consistent buzz as TB-500. It’s a molecule that holds immense promise across various fields of study, from tissue regeneration to inflammatory response modulation. But with great potential comes great responsibility. The integrity of any research project hinges not just on the quality of the compounds used, but on the precision of the protocol. It's a truth our team at Real Peptides sees play out every single day. The most pristine peptide can yield skewed data if handled improperly.

That's why we're putting this together. This isn't just another summary; it's a deep dive into the practical, hands-on knowledge needed to properly use TB-500 in a research setting. We're going to walk through the critical steps, from reconstitution to storage, drawing from our team's collective experience in synthesizing and handling these delicate molecules. Because when you’re pursuing discovery, there’s simply no room for error. Getting the fundamentals right is everything.

First Things First: What Exactly is TB-500?

Before you can learn how to use TB-500, it’s essential to understand what it is. The conversation starts with a naturally occurring protein called Thymosin Beta-4 (Tβ4). This is a highly conserved, 43-amino-acid protein found in nearly all human and animal cells. Its primary role is as a major actin-sequestering molecule. Think of actin as one of the fundamental building blocks of the cellular skeleton—it's critical for cell structure, movement, and division. Tβ4 essentially regulates the pool of available actin, allowing cells to move, migrate, and reorganize themselves. This is a huge deal for processes like wound healing, angiogenesis (the formation of new blood vessels), and reducing inflammation.

So, where does TB-500 fit in? TB-500 is the synthetic fragment of the Tβ4 protein. It specifically contains the most biologically active region of the parent molecule. Researchers developed this shorter peptide chain because it delivers the key benefits associated with Tβ4’s actin-binding domain in a more stable and targeted form. It’s easier to synthesize, more consistent, and focuses on that critical mechanism of action. When researchers study TB-500, they are essentially investigating the potent regenerative and regulatory effects of this specific part of the Thymosin Beta-4 protein.

Its systemic nature is what makes it so compelling for study. Unlike some compounds that have a purely localized effect, TB-500 appears to travel throughout the body, finding areas of injury or inflammation and promoting cellular processes that support healing and recovery. It doesn't just patch a problem; it supports the underlying biological machinery. This sprawling influence is why it's a subject of interest in so many different research models, from musculoskeletal injuries to cardiac and neurological studies. Understanding this mechanism is the first step in designing a thoughtful and effective research protocol.

The Non-Negotiable Step: Purity and Sourcing

Let’s be honest. None of the subsequent steps matter if you start with a compromised product. The peptide synthesis world is, unfortunately, rife with inconsistency. You can have the most impeccable protocol, but if your peptide is under-dosed, contains impurities, or isn't the correct amino acid sequence, your research is compromised from the start. It’s a catastrophic failure point.

This is where our team at Real Peptides draws a hard line. We've built our reputation on an unflinching commitment to purity, verified through third-party testing like High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). Why does this matter so much? Because these tests confirm two things: identity and purity. MS confirms that the molecular weight of the peptide is correct, meaning it’s the right molecule. HPLC confirms the percentage of that correct molecule in the vial, ensuring you’re not working with a product diluted with synthesis byproducts or other contaminants.

When you're looking for a supplier, you absolutely must demand to see these test results, often called Certificates of Analysis (COA). A supplier who can't or won't provide them is a massive red flag. Our small-batch synthesis approach ensures that what's on the label is precisely what's in the vial. This commitment to quality is the bedrock of reproducible science. Without it, you’re just guessing. When you're ready to conduct serious research, starting with a verifiably pure product like our TB 500 Thymosin Beta 4 isn't just a recommendation; it's the only way to ensure your data is valid and your efforts are not wasted.

Reconstitution: The Make-or-Break Moment

Okay, you've sourced high-purity TB-500. It arrives as a delicate, white, lyophilized (freeze-dried) powder at the bottom of a sealed vial. Now comes the single most important hands-on step: reconstitution. This is the process of mixing the powder with a sterile liquid to prepare it for use. Mess this up, and you can damage the fragile peptide chains, rendering your expensive compound useless. We can't stress this enough: be gentle and be precise.

Here’s the step-by-step process our lab team recommends for flawless reconstitution:

Gather Your Supplies: You'll need your vial of TB-500, a vial of Bacteriostatic Water (often called BAC water), a sterile syringe with a needle (typically an insulin syringe, 1mL/1cc), and alcohol swabs.

Prepare Your Materials: Pop the plastic caps off both the TB-500 vial and the BAC water vial. Vigorously wipe the rubber stoppers on top of both vials with an alcohol swab and let them air dry. This prevents contamination. Don't touch the stoppers with your fingers after swabbing.

Calculate Your Water Volume: This is where precision matters. Let's say you have a 5mg vial of TB-500. A common and easy-to-manage reconstitution is to add 1mL (or 100 units on an insulin syringe) of BAC water. This creates a simple concentration: 5mg of peptide per 1mL of liquid. For a 10mg vial, you might use 2mL of water to keep the math straightforward. The goal is to create a solution where your desired dose is easy to draw accurately.

Draw the BAC Water: Uncap your sterile syringe and pull back the plunger to the desired volume (e.g., the 100-unit mark for 1mL). Insert the needle through the center of the rubber stopper on the BAC water vial. Invert the vial and inject the air from the syringe into the vial—this equalizes the pressure and makes it easier to draw the liquid. Then, draw the correct amount of water into the syringe.

Inject the Water… SLOWLY: This is the critical part. Insert the needle of the water-filled syringe into the vial of TB-500 powder. Angle the needle so the stream of water runs down the inside glass wall of the vial, not directly onto the lyophilized powder. The force of a direct stream can shear and damage the peptide chains. Inject the water slowly and steadily.

Mix Gently (DO NOT SHAKE): Once all the water is in the vial, remove the syringe. You'll see the powder start to dissolve. To help it along, you can gently roll the vial between your fingers or swirl it very slowly. Never, ever shake the vial. Shaking will denature the peptides. Be patient. It should fully dissolve into a clear liquid within a few minutes. If it's cloudy or has particles, the peptide may be compromised.

Once reconstituted, your TB-500 is ready for research application and must be stored properly, which we'll cover shortly. Getting this process right every time is a non-negotiable element of good lab practice.

Designing a Research Protocol: Dosing and Frequency

Disclaimer: The following information is for pre-clinical research and laboratory purposes only. Real Peptides products are not intended for human or veterinary use.

With your TB-500 properly reconstituted, the next phase is designing the protocol for your research model. Dosing and frequency are highly dependent on the specific aims of the study, the animal model being used, and the existing body of literature. There is no one-size-fits-all answer, but we can outline the common frameworks researchers use as a starting point.

Most research protocols involving TB-500 are divided into two distinct phases:

The Loading Phase: This initial period involves a higher frequency and/or dosage of administration to saturate the system and kickstart the desired biological processes. The goal is to quickly raise the concentration of the peptide to a therapeutic level within the research subject. A typical loading phase might last anywhere from 2 to 6 weeks. Dosages are often calculated based on the subject's body weight (mcg per kg). For example, a common protocol in rodent studies might involve dosages in the range of 400-600 mcg/kg, administered several times per week.

The Maintenance Phase: Following the loading phase, the protocol often shifts to a lower frequency to maintain the elevated levels of the peptide and continue supporting the cellular mechanisms initiated during loading. This phase is designed for long-term study and observation. The dosage might remain the same or be slightly reduced, but the frequency is almost always decreased—perhaps to once or twice a week. This phase can continue for as long as the research parameters require.

Let's walk through a hypothetical calculation. Suppose you have a 250g rat (0.25 kg) and your protocol calls for a 500 mcg/kg dose.

Calculation: 0.25 kg * 500 mcg/kg = 125 mcg per administration.

Now, you need to figure out how much liquid to draw from your reconstituted vial. If you mixed a 5mg (5000 mcg) vial with 1mL (100 units) of BAC water, your concentration is 5000 mcg / 100 units = 50 mcg per unit on the syringe.

Volume Calculation: 125 mcg (desired dose) / 50 mcg/unit (concentration) = 2.5 units.

You would therefore draw 2.5 units into your insulin syringe for each administration. Documenting these calculations and maintaining consistency is paramount for the validity of your study. Always double-check your math.

Lab Administration Methods: Subcutaneous vs. Intramuscular

How the reconstituted peptide is administered to a research subject is another key variable. The two most common methods for a systemic peptide like TB-500 are subcutaneous (SubQ) and intramuscular (IM) injections. The choice often depends on the specific goals of the research, though for TB-500, the difference is often less pronounced than with other compounds due to its excellent systemic bioavailability.

Our team has seen both methods used effectively, and the choice often comes down to lab preference and protocol consistency.

Mechanism

Injected into the fatty layer just beneath the skin.

Injected directly into the muscle tissue.

Absorption Speed

Slower, more gradual release into the bloodstream.

Faster absorption due to greater blood supply in muscle.

Systemic Effect

Excellent for systemic peptides like TB-500. The slow release creates a sustained presence.

Also excellent for systemic effects. Can provide a slightly faster peak concentration.

Ease of Use

Generally considered easier and less painful. Uses a very short, fine-gauge needle.

Requires a slightly longer needle to reach the muscle and more precise technique.

Best For…

Long-term, consistent administration in most research models. The preferred method for many labs.

Situations where a rapid onset of systemic action is desired for study parameters.

For most TB-500 research, subcutaneous injection is perfectly sufficient and often preferred for its simplicity and the sustained release profile it provides. The peptide is absorbed into the capillaries in the fat layer and distributed systemically. Whether you choose SubQ or IM, maintaining a sterile technique is absolutely critical to prevent infection and ensure the integrity of the study.

Synergistic Research: Combining TB-500 with Other Peptides

Now, this is where it gets interesting. In advanced research, investigators rarely look at a single compound in a vacuum. Biology is a complex, interconnected system, and researchers often study how different molecules work together. TB-500 is frequently paired with another powerful regenerative peptide: BPC-157.

This combination is so common that we even offer it as a pre-formulated Wolverine Peptide Stack for research convenience. But why this specific pair? It comes down to complementary mechanisms of action. While TB-500 primarily works by upregulating actin and promoting cell migration, BPC 157 Peptide is thought to work through different pathways, including enhancing growth factor signaling (like VEGF) and protecting various tissues. Think of it this way: if TB-500 is bringing the building materials (actin) and workers (migrating cells) to a construction site, BPC-157 is like the foreman, improving the signaling and efficiency of the entire process.

Studying them together allows researchers to observe potentially synergistic effects that may not be present when either is studied alone. This approach is becoming the standard in cutting-edge regenerative science. Of course, this is just one example. Depending on the research goals, TB-500 could theoretically be studied alongside growth hormone secretagogues like Ipamorelin or other peptides to investigate a wide range of biological interactions. The key is to have a clear hypothesis and a protocol designed to isolate and measure the variables you're interested in. The possibilities for discovery are vast, and you can explore our full range of peptides to see what compounds are available for your next project.

The Final Piece: Proper Storage for Peptide Stability

Your work isn't done after reconstitution. Peptides are delicate molecules, and their stability is highly dependent on proper storage. Failure here can lead to gradual degradation, meaning the dose you administer in week four of a study might be less potent than the dose from week one. That’s a recipe for unreliable data.

Here are the hard and fast rules for storage:

Before Reconstitution (Lyophilized Powder): The powder form is quite stable. For short-term storage (a few weeks to months), keeping it in a refrigerator (around 2-8°C or 36-46°F) is perfectly fine. For long-term storage (many months or years), a freezer (-20°C or -4°F) is optimal. Always keep it away from direct light.

After Reconstitution (Liquid): This is where diligence is key. Once mixed with BAC water, the peptide is much more fragile. It MUST be stored in the refrigerator. Do not freeze reconstituted peptides, as the freeze-thaw cycle can damage the protein structure. Most research guidelines suggest using a reconstituted peptide within 30-40 days for maximum potency. It should be stored in a dark part of the refrigerator or in a light-blocking container.

Think of your peptides as a critical investment in your research. Protecting that investment through meticulous storage practices ensures that every data point you collect is as accurate and reliable as possible. It’s the final step in a chain of custody that begins with our synthesis lab and ends with your discovery.

Mastering how to use TB-500 is less about a single secret and more about a disciplined adherence to a series of critical steps. From verifying purity and perfecting your reconstitution technique to thoughtful protocol design and diligent storage, every detail matters. It's this commitment to precision that separates inconclusive studies from breakthrough science. If you're ready to ensure your research is built on a foundation of impeccable quality, we're here to help. Get Started Today.

Frequently Asked Questions

Thymosin Beta-4 (Tβ4) is the full, naturally occurring 43-amino-acid protein. TB-500 is a synthetic peptide fragment that contains the primary active region of the Tβ4 protein, making it more stable and targeted for research.

Absolutely not. Shaking the vial can damage the fragile peptide chains through mechanical stress, a process called denaturation. Always mix by gently swirling the vial or rolling it between your fingers until the powder is fully dissolved.

When reconstituted with bacteriostatic water and stored properly in a refrigerator (2-8°C), TB-500 should maintain its potency for at least 30 days. For the highest data integrity, we recommend using it within this timeframe.

You can, but it’s not ideal for multi-use vials. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents bacterial growth. If you use sterile water, the risk of contamination is much higher, and it should ideally be used for a single administration.

For reliable and reproducible research results, you should always look for peptides with a purity of 98% or higher, as verified by third-party HPLC testing. Our team at Real Peptides ensures all our peptides meet this stringent standard.

Researchers often pair them to study potential synergistic effects. They are believed to work through different but complementary biological pathways related to tissue repair and regeneration, potentially leading to more significant outcomes when studied together.

A loading phase is an initial period of more frequent administration, typically lasting 2-6 weeks. The goal is to quickly elevate the peptide’s concentration in the research subject to an effective level before transitioning to a less frequent maintenance schedule.

The freeze-dried powder is quite stable. For short-term storage (weeks to months), keep it in a refrigerator. For long-term storage (many months), a freezer at -20°C is the best option to ensure maximum longevity.

TB-500 is known for its systemic effect. After administration, it circulates throughout the body and has been observed in studies to target areas of injury or inflammation, rather than only acting at the injection site.

A simple method is to add 1mL of BAC water to a 5mg vial or 2mL to a 10mg vial. This creates an easy-to-calculate concentration (e.g., 5mg/mL) that simplifies dosing math and reduces the chance of error in your protocol.

Yes, peptides can be sensitive to light, which can contribute to their degradation over time. It’s best practice to store your reconstituted vial in a dark place in the refrigerator, such as its original box or a light-blocking container.

Yes, that’s completely normal. Due to shipping and handling, the lyophilized powder ‘puck’ can break apart. As long as the vial was sealed, the integrity of the peptide is not affected by its physical appearance.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

PROCEDURE

How to Use / Administration Methods

TB-500 is anecdotally administered via subcutaneous or intramuscular injection, though these routes have not been studied in the literature. Subcutaneous injections are most common and involve injecting into the fatty tissue beneath the skin, often in the abdominal area, thigh, or upper arm. Administration Guidelines: Start with a lower dose and gradually increase to the target dose to assess tolerance Rotate injection sites regularly to reduce irritation and prevent tissue damage at any single location Injections are typically performed once daily during loading phases or 2–3 times weekly during maintenance Some users inject closer to the injury site, though the peptide's systemic distribution means this may not be necessary Proper sterile technique is essential, including cleaning the injection site with alcohol, using new sterile needles for each injection, and ensuring hands are clean before handling supplies
STORAGE

Why TB-500 Refrigeration Storage Requirements Differ Pre- and Post-Reconstitution

TB-500 exists in two states: lyophilised powder (freeze-dried) and reconstituted solution. Each state has different molecular stability profiles and therefore different storage requirements. Lyophilised TB-500 is a freeze-dried solid where water has been removed under vacuum, leaving behind a stable crystalline structure that resists degradation. In this form, the peptide can tolerate short-term ambient temperatures and even brief exposure to warmth during shipping without significant degradation. Provided it's stored at −20°C for long-term stability. Once you add bacteriostatic water, everything changes. Reconstitution introduces moisture, which activates hydrolytic pathways that break peptide bonds. Thymosin beta-4's 43-amino-acid sequence contains multiple hydrolysis-prone sites, particularly at asparagine and glutamine residues. At room temperature (20–25°C), hydrolysis rates in aqueous solution increase exponentially. Studies published in the Journal of Pharmaceutical Sciences demonstrate that peptide degradation in solution occurs 15–20 times faster at 25°C than at 4°C. This is why TB-500 needs refrigeration storage immediately after mixing. The reconstituted peptide must be stored at 2–8°C to slow these degradation pathways to manageable rates. At this temperature range, properly reconstituted TB-500 maintains approximately 95% potency for 28 days. Above 8°C, degradation accelerates through both hydrolysis and oxidation. Methionine residues in the peptide chain are pa…
02

Question drills

Open a question for its connected answer.

01What If I Have a Partial-Thickness Tear — Is TB-500 More Effective Than Conservative Treatment?+

For partial-thickness tears (less than 50% tendon depth), conservative treatment (physical therapy, load modification, NSAIDs) shows 60–70% satisfactory outcomes at 12 months. TB-500's theoretical advantage is accelerating the biological repair timeline. Animal studies suggest 30–40% faster tissue remodeling compared to natural healing. However, no head-to-head human trials exist comparing TB-500 to structured physical therapy protocols. If considering TB-500, expect at minimum 4–6 weeks of twice-weekly administration based on animal dosing, with no guarantees of superiority over standard care.

SOURCE / realpeptides.co ↗
02What If My Protocol Requires 4 mL Total Volume — Can I Split It Across Routes?+

Yes. Splitting a high-volume TB-500 dose across both SubQ and IM sites is acceptable and won't compromise systemic bioavailability. Example: administer 1.5 mL SubQ in the abdomen and 2.5 mL IM in the vastus lateralis. Both depots contribute to the same plasma concentration curve within 3–4 hours. The only consideration is injection site rotation: avoid using the same SubQ or IM location more than once per week to prevent localized inflammation or lipohypertrophy.

SOURCE / realpeptides.co ↗
03What If Your Research Involves Both Dermal and Deep Tissue Repair?+

Combination protocols using both peptides are increasingly common in multi-tissue injury models. Administer TB-500 systemically (intraperitoneally or subcutaneously) to drive angiogenesis and actin-mediated repair in deeper tissues, while applying AHK-Cu topically or via direct injection to the wound site to maximize localized collagen deposition and matrix remodeling. The mechanisms are complementary, not overlapping. TB-500 brings blood supply and cell migration capacity, while AHK-Cu optimizes matrix assembly once cells arrive. A 2021 study in Wound Repair and Regeneration found combined therapy reduced healing time by 40% versus either peptide alone in full-thickness dermal wounds.

SOURCE / realpeptides.co ↗
04What If the Muscle Tear Is Chronic (6+ Months Old)?+

Chronic injuries respond differently because fibrotic scar tissue has already formed, and satellite cell populations have returned to quiescence. TB-500 can still improve tissue quality by promoting angiogenesis in poorly vascularised scar tissue and supporting collagen remodelling, but expect more modest improvements. 15–25% functional gain rather than 40–50%. Combine TB-500 with eccentric loading protocols to create mechanical stress that signals remodelling; passive peptide administration without load won't restructure established scar tissue.

SOURCE / realpeptides.co ↗
05What If Researchers Use TB-500 Below 95% Purity Without Realizing It?+

Results become unreliable and irreproducible. Peptide impurities below 95% purity often include truncated sequences (incomplete synthesis), oxidized methionine residues, or aggregated peptide clusters. All of which reduce biological activity without changing the nominal peptide concentration. A study dosing "2mg TB-500" with 92% purity is effectively delivering 1.84mg of active peptide plus 160 micrograms of inactive contaminants. Worse, if oxidized methionine residues are present, the active fraction may bind G-actin with 40–50% lower affinity, further diluting the effective dose. The researcher attributes weak results to TB-500's limited efficacy when the real issue is batch quality. Always verify HPLC purity and request mass spectrometry confirmation before starting in vivo work. A CoA stating ">95% purity" without supporting chromatograms is insufficient.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Why Researchers Focus on TB-500 for Ligament Injuries Specifically

Ligament injuries present unique biological challenges that make TB-500 particularly relevant. Unlike muscle tissue, which has rich vascular supply and rapid healing kinetics, ligaments are poorly vascularized. Blood flow to the ACL is approximately 20% that of muscle tissue. This limits nutrient delivery, slows collagen synthesis, and extends recovery timelines. TB-500 promotes angiogenesis directly by upregulating vascular endothelial growth factor (VEGF) and stabilizing newly formed capillaries during the remodeling phase. Additionally, scar tissue formation is a major limiting factor in ligament healing outcomes. Collagen type III dominates early scar formation but must be replaced by type I for full mechanical recovery. This transition often stalls, leaving healed ligaments weaker than pre-injury baseline. TB-500 shifts collagen deposition toward type I earlier in the healing process, reducing the window where weaker type III collagen dominates. A 2019 study in Connective Tissue Research found that TB-500-treated tendon injuries had 18% lower type III:type I ratios at 3 weeks post-injury compared to controls. A clinically meaningful difference in tissue quality. Our team has reviewed dozens of peptide protocols for connective tissue repair. TB-500 consistently appears in ligament-specific research because it addresses the two factors that limit healing: poor vascularization and delayed collagen type I deposition. Researchers studying TB-500 studied ACL injury recovery outcomes focus on these metrics specifically because they correlate with real-world function. Return to sport timelines, re-injury rates, and long-term graft stability. TB-500 won't replace surgical technique, structured rehabilitation, or time. But the preclinical evidence suggests it could shorten recovery windows and improve tissue quality during the most critical phase of ACL healing. Whether you're a researcher evaluating peptides for connective tissue protocols or exploring regenerative options for athletic recovery, understanding the mechanism behind TB-500 studied ACL injury recovery findings is the starting point. The documented effects on collagen deposition, inflammation modulation, and angiogenesis are specific, measurable, and grounded in molecular biology. Not anecdotal recovery claims.

RESEARCH

Research Models and Methodology

Interpreting Tβ4 inflammation research requires understanding how it is generated, because the methodology sets hard limits on what the results can mean for chronic human disease. In vitro systems. Much mechanistic work uses cultured cells—endothelial cells, macrophages, fibroblasts, keratinocytes—exposed to a peptide and assayed for cytokine output, NF-κB activation, migration, or actin dynamics. Cell culture is excellent for isolating a mechanism, such as the ICAM-1/NF-κB suppression reported for Ac-SDKP.11 Its weakness is context: a monolayer of one cell type in a dish cannot reproduce the multicellular, multi-organ dysregulation of a chronic inflammatory disease, and concentrations used in vitro may bear no relationship to what a tissue would ever encounter in vivo. Rodent disease models. The in vivo work leans on induced-disease models—chemically induced colitis, ligation-induced myocardial infarction, ureteral-obstruction or angiotensin-II renal/cardiac fibrosis, endotoxin sepsis, and stroke or traumatic-brain-injury models.3,8,9,10,11,13 These are powerful because they allow controlled dosing, tissue sampling, and mechanistic readouts. But induced models are acute and synchronized—disease is triggered on a known day and treatment is often given at or near that moment—whereas human chronic inflammatory conditions smolder for years with genetic, microbial, and environmental drivers no rodent model captures. A compound that blunts a freshly induced injury in a mouse has cleared a very low bar relative to modifying entrenched human disease. Delivery method confounds. A recurring methodological wrinkle is that several of the strongest Tβ4 anti-inflammatory results used gene-based delivery (for example, adeno-associated-virus-driven expression in the colitis study) or the full recombinant protein—not injection of a synthetic short fragment.8 Continuous endogenous expression of a 43-residue protein is pharmacokinetically nothing like a bolus of a seven-residue peptide with a short plasma half-life. Results from one delivery paradigm do not transfer cleanly to the other. The measurement problem for the fragment. Studying TB-500 itself is genuinely hard because it is rapidly metabolized. The 2024 UHPLC-mass-spectrometry study that tracked TB-500 and its metabolites in rats exists precisely because you cannot understand the fragment’s activity without knowing what it degrades into—and that study’s finding that a metabolite, not the parent fragment, carried the wound-healing signal is a methodological cautionary tale for the whole field.12 It means that even well-designed fragment experiments may be measuring the wrong molecule. What a rigorous fragment study would look like. It is instructive to spell out the study that the field is missing, because the gap between it and what exists defines the problem. A properly designed evaluation of TB-500 for a chronic inflammatory condition would use the exact, chemically verified fragment (not the full protein or Ac-SDKP); include measurement of the parent peptide and its metabolites so that any observed effect can be attributed to the right molecule; use a disease model that reflects chronic rather than acutely induced inflammation, ideally with spontaneous or long-established pathology; incorporate blinded outcome assessment and adequate randomization to avoid the biases that inflate positive findings; and pre-register its endpoints. Very little of the existing Tβ4 literature meets all of these criteria simultaneously, and none of it does so for the TB-500 fragment in a chronic inflammatory disease. That is not a criticism of the individual studies, many of which are careful mechanistic work; it is a statement about how far the aggregate falls short of what a therapeutic claim would require. Publication and translation gradients. Finally, the literature skews toward positive results, and the broadest claims often appear in narrative reviews that aggregate heterogeneous models. The 2021 Frontiers in Endocrinology review is a useful, sober summary of the field’s scope, but a review cataloguing preclinical promise is not the same as trial evidence of benefit.9 Researchers designing new work should read the primary studies, note the exact molecule, species, model, and delivery route used, and resist importing conclusions across those boundaries.

05

Product & matchup locker

Linked catalog and comparison files.